SuperworthInteger ITGR
- Market cap
- $4.3B
- PE
- 34.6×
- 10y median 33.5×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.3×
- EV/EBIT
- 29.7×
- Revenue, 12 months
- $1.8B
- +3% on a year ago
- Net margin
- 7.0%
- Free cash flow yield
- 2.6%
Integer trades at 34.6× trailing earnings, near its ten-year median. Revenue was $1.8B over the last twelve months, up 3% on a year earlier with a 7% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $396.8M+16% | $413.2M+11% | $407.8M+8% | $427.9M+7% | $431.4M+9% | $449.5M+9% | $437.4M+7% | $476.5M+11% | $467.7M+8% | $472.1M+5% | $439.6M+1% | $464.1M−3% | |
| Cost of revenue | $291.8M+14% | $302.9M+10% | $299.5M+6% | $310.5M+6% | $314.8M+8% | $332.7M+10% | $317.1M+6% | $347.3M+12% | $341.5M+9% | $347.3M+4% | $330M+4% | $351.2M+1% |
| Gross profit | $105M+21% | $110.3M+13% | $108.3M+12% | $117.4M+11% | $116.6M+11% | $116.8M+6% | $120.3M+11% | $129.2M+10% | $126.2M+8% | $124.8M+7% | $109.6M−9% | $112.9M−13% |
| R&D | $14.1M−13% | $13.1M−6% | $15.3M−20% | $15.6M−8% | $11.9M−15% | $10.6M−19% | $14.2M−7% | $14.2M−9% | $10.9M−8% | $10.1M−5% | $16.2M+14% | $11.3M−21% |
| SG&A | $41.4M+9% | $45.3M+10% | $46.4M+11% | $46.5M+1% | $44.8M+8% | $47.5M+5% | $51.2M+10% | $52.9M+14% | $50.5M+13% | $57.2M+21% | $58.7M+15% | $57.7M+9% |
| $48.8M+67% | $43.5M+18% | $38.7M+13% | $54.5M+31% | $58M+19% | $57M+31% | $49.6M+28% | $59.3M+9% | $56.4M−3% | $55.9M−2% | $31.9M−36% | $34.5M−42% | |
| Interest expense | $11.5M+8% | $12.1M−15% | $14M−19% | $14.6M+27% | $14.6M+27% | $13.2M+10% | $14.8M+6% | $9.8M−33% | $9.4M−36% | $9.3M−30% | $9.7M−34% | $10.1M+4% |
| Pre-tax income | $33.3M+96% | $29.3M+42% | $24.8M+55% | $40M+34% | $43.4M+31% | $39.3M+34% | −$13M | $45.6M+14% | $46M+6% | $46.8M+19% | $20.4M | $23.3M−49% |
| $5.1M+441% | $3.2M−10% | $4.2M+45% | $8.8M+49% | $7.1M+41% | $6.3M+98% | $9.5M+123% | $8.6M−3% | $6.3M−12% | −$1.8M | $3.8M−59% | −$314K | |
| Net income | $27.3M+70% | $26.4M+46% | $20.5M+57% | $31.2M+30% | $35.4M+30% | $32.7M+24% | −$22.5M | $37M+18% | $39.7M+12% | $48.6M+49% | $16.5M | $23.6M−36% |
| $0.81+69% | $0.78+44% | $0.59+51% | $0.88+24% | $0.99+22% | $0.90+15% | −$0.66 | $1.04+18% | $1.11+12% | $1.38+53% | $0.48 | $0.69−34% | |
| 33.8M+1% | 34M+2% | 35M+4% | 35.5M+6% | 35.8M+6% | 36.2M+7% | 33.9M−3% | 35.7M+1% | 35.6M−1% | 35.1M−3% | 34.4M+2% | 34.1M−4% |
Revenue: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
R&D: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
SG&A: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Operating income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Income tax: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Net income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
EPS, diluted: 11 periods, Q1 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY10: share-days: the 6-month average less the second quarter's. 13 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY12 and Q4 FY15: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY16: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Devices nearest Integer's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ITGRInteger | $4.3B | 34.6× | 33.5× | n/m | 2.3× | +3% | 7.0% |
| LIVNLivaNova | $4.5B | 23.9× | 72.5× | n/m | 3.0× | +12% | 12.8% |
| TMDXTransMedics | $2.5B | 18.4× | 56.8× | n/m | 3.7× | +26% | 22.7% |
| CNMDCONMED | $1.5B | 26.6× | 53.0× | n/m | 1.1× | +3% | 4.1% |
| ZBHZimmer Biomet | $18.8B | 24.0× | 31.4× | n/m | 2.2× | +9% | 9.5% |
| DXCMDexCom | $29.4B | 30.9× | 102× | 27.7× | 5.9× | +16% | 20.1% |
| GEHCGE HealthCare Technologies | $32.3B | 16.4× | 17.0× | 13.8× | 1.5× | +7% | 9.3% |
| Peer median | $11.6B | 23.9× | 54.9× | 20.8× | 2.6× | +11% | 11.1% |
More on Integer
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 12Medical device stocks with the fastest earnings growth
- #10of 26Medical device stocks with the lowest price to sales ratio
Its groups
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .